Trevena, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 07:16 am EDT
Share
Trevena, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 3.02 million. Net loss was USD 8.01 million compared to USD 14.98 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 2.26 a year ago.
For the six months, revenue was USD 3.03 million compared to USD 0.02 million a year ago. Net loss was USD 15.83 million compared to USD 31.37 million a year ago. Basic loss per share from continuing operations was USD 1.49 compared to USD 4.74 a year ago.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companyâs pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
TREVENA, INC. 
